Tuberculosis is not a virus. It is caused by a bacterium called Mycobacterium tuberculosis, a single-celled organism that can reproduce on its own, something no virus can do. This distinction matters because it determines how TB spreads, how it’s diagnosed, and how it’s treated. Viruses require a host cell to replicate, while TB bacteria divide independently inside the body, often settling deep in the lungs.
Why TB Is a Bacterium, Not a Virus
Mycobacterium tuberculosis is classified as a prokaryote, the same broad category that includes bacteria responsible for strep throat, staph infections, and food poisoning. What makes it unusual, even among bacteria, is its cell wall. Most bacteria have relatively simple outer layers, but TB bacteria are surrounded by a thick, waxy shell made of fatty molecules layered over a rigid inner scaffold. This complex armor is one reason the bacterium is so hard to kill and why TB treatment takes months rather than days.
Viruses, by contrast, are far simpler. They’re essentially packets of genetic material wrapped in a protein coat. They can’t grow, divide, or carry out any life functions until they hijack a living cell’s machinery. TB bacteria don’t need to do this. Once inside your lungs, they divide on their own, doubling slowly compared to most other bacteria. During the early phase of infection, the bacteria replicate steadily. If the immune system manages to contain them, they can shift into a near-dormant state, persisting for years with very little activity.
How TB Spreads
TB travels through the air. When someone with active TB in the lungs coughs, speaks, or sings, they release tiny particles called droplet nuclei that carry the bacteria. These particles are small enough to remain suspended in the air for several hours, depending on ventilation. Anyone who breathes them in can become infected.
This is different from many viral infections that spread through direct contact or larger respiratory droplets that fall quickly to surfaces. TB transmission typically requires shared air space with an infectious person, often in enclosed or poorly ventilated environments.
Latent vs. Active TB
Most people who inhale TB bacteria don’t get sick right away. The immune system walls off the bacteria, creating a condition called latent TB. You carry the infection but have no symptoms and can’t spread it to others. Roughly 5% to 15% of people with latent TB will eventually develop active disease at some point in their lives.
What tips the balance is usually a weakened immune system. HIV infection is one of the strongest risk factors. Diabetes, smoking, cancer, organ transplants, and medications that suppress immune function (such as those used for autoimmune diseases) all raise the risk. Aging also plays a role, as the immune system naturally becomes less effective over time. When the bacteria reactivate, they begin multiplying again, causing the cough, fever, night sweats, and weight loss associated with active TB.
How TB Is Diagnosed
Because TB is bacterial, doctors can test for the immune response it triggers or detect the bacteria directly. The two most common screening methods are a skin test and a blood test.
The blood test, known as an interferon-gamma release assay (IGRA), works by mixing a blood sample with proteins that mimic TB antigens. If your white blood cells have encountered TB bacteria before, they respond by releasing a signaling molecule. The lab measures that response to determine whether you’ve been infected. Results are typically available within 24 to 48 hours. This test is especially useful for people who received the BCG vaccine as children, since the skin test can produce false positives in vaccinated individuals.
If screening is positive, a chest X-ray and sputum samples help determine whether the infection is latent or active. Active TB shows characteristic lung damage on imaging, and lab cultures can confirm the presence of live bacteria.
Treatment Takes Months, Not Days
This is where the bacterial classification has the biggest practical impact. Because TB is caused by bacteria, it’s treated with antibiotics. Because of that unusually thick cell wall and the bacterium’s ability to enter a slow-growing dormant state, standard treatment requires four antibiotics taken over six to nine months.
The regimen starts with a two-month intensive phase using all four drugs simultaneously. After that, a continuation phase lasting four to seven additional months uses a smaller combination. The lengthy course is necessary because dormant bacteria are harder to reach, and stopping early is one of the main reasons drug-resistant strains develop.
Viral infections, for comparison, are treated with antiviral drugs or managed with supportive care. Antibiotics have no effect on viruses. If TB were viral, the entire treatment strategy would be fundamentally different.
Drug-Resistant TB
One consequence of TB’s bacterial nature is the risk of antibiotic resistance. Multidrug-resistant TB (MDR-TB) occurs when the bacteria evolve to survive the two most powerful first-line antibiotics. The World Health Organization estimated that roughly 410,000 people developed multidrug-resistant or rifampicin-resistant TB in 2022. Treatment for resistant strains takes longer, involves more drugs with harsher side effects, and has lower success rates.
Resistance develops most often when patients don’t complete their full treatment course, when prescribing is inadequate, or when drug supply is inconsistent. It’s a problem unique to bacterial infections, since the mechanism depends on bacterial DNA mutating during replication.
Vaccination and Global Impact
The only available TB vaccine, BCG, has been in use for over a century. It provides moderate protection for young children, reducing TB risk by about 37% in children under five. For pulmonary TB specifically, efficacy drops to around 19%, and researchers have not found conclusive evidence that the vaccine protects older children or adults. This limited effectiveness is one reason TB remains so widespread.
Globally, TB caused an estimated 10.8 million new infections and 1.25 million deaths in 2023, making it one of the deadliest infectious diseases on the planet. It kills more people annually than HIV. The combination of airborne spread, a vaccine with limited reach, and treatment that demands months of consistent medication explains why a bacterium identified over 140 years ago continues to be a leading cause of death worldwide.